current under-valued mor upsid
adjust revenu earn estim base system headwind
expect interrupt offic visit new prescript
meanwhil partner mor confirm delay tafasitamab bla review
process pdufa still track despit remain optimist
potenti synergi overlap tafasitamab jakafi commun
set mor alreadi engag kol mor also
initi seri joint clinic trial broaden treatment scope tafasitamab
move earlier line provid catalyst updat
model lower sale jakafi olumi iclusig due
disrupt drive new detail insid
mor confirm delay tafasitamab bla review process despit
pandem manufactur site inspect fda remain
schedul although yet model anticip tafasitamab revenu
offset lower sale product includ jakafi due disrupt
new script histor total script forecast jakafi
mor us commerci organ activ sale rep hire
expect synergi overlap tafasitamab jakafi commun
set mor co-commerci tafasitamab us
p/l ex-u right tafasitamab exhibit
tafasitamab expand access program eap us patient inelig
clinic trial began confid tafasitamab clinic potenti
base l-mind result primari endpoint
mpf month mdor month mo reach ci
month nr tr-sae patient infect neutropenia
clinic trial seri broaden treatment scope tafasitamab
move earlier line anticip catalyst includ first-mind trial
dlbcl readout pivot trial triplet tafasitamab lenalidomid
r-chop vs r-chop dlbcl initi trial tafasitamab
parsaclisib r/r-cll/nhl initi pivot trial r/r-fl/mzl
although lower sale forecast jakafi olumi iclusig topic
ruxolitinib due disrupt result lower pt vs
prior view current under-valued rel nasdaq biotech index
ytd vs nbi note ampl near-term catalyst
believ restor investor confid exhibit
biopharma compani
focus small molecul oncolog
jakafi
year price histori incyt
analyst certif import disclosur see disclosur
jakafi success commerci gvhd
topic ruxolotinib approv dermatolog condit
accret invest cash rel low-risk pipelin asset
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig deep promis pipelin
includ capmatinib divers pipelin drive
acceler revenu growth current under-valu
view
result ruxolitinib cream
potenti fda approv pemigatinib cca
poc data mf
file tafasitamab dlbcl
potenti fda approv tafasitamab dlbcl
result ruxolitinib sr-cgvhd
potenti fda approv capmatinib nsclc
nda file ruxolitinib cream atop dermat
initi mf
result itacitinib sn-cgvhd
higher expect sale market product
greater expect advanc pipelin asset
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale
could peak us includ peak royalti ex-u sale see iclusig olumi smaller contributor
revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit oppenheim vs consensu estim annual jakafi sale
exhibit oppenheim vs consensu estim annual total revenu
exhibit mor us commerci organ activ believ partnership
synergi overlap tafasitamab jakafi commun set
exhibit incy/mor joint clinic trial seri broaden treatment scope tafasitamab
move earlier line note sever key upcom catalyst
exhibit believ sever near-term catalyst restor investor confid
exhibit pt support dcf valuat
discount analysisoppenheim co except per-shar data revenu chang work work capit valu growth valu oppenheim co estimatesequ valu per sharetermin valu growth rate
thousand except per share
product royalti revenu olumi us eu row
probabl success
probabl success
probabl success
probabl success
probabl success
mileston contract research
probabl success
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
share-bas compens cog
share-bas compens cog expens
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
ep basic dilut
ep non-gaap basic dilut
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
co nyse cover
